UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Date of report (Date of earliest event reported): August 27, 2013

 

Bacterin International Holdings, Inc.

	(Exact Name of Registrant as Specified in Its Charter)
	Delaware
	(State or Other Jurisdiction of Incorporation)
	001-34951	20-5313323
	(Commission File Number)	(IRS Employer Identification No.)
	600 Cruiser Lane Belgrade, Montana	59714
	(Address of Principal Executive Offices)	(Zip Code)
(406) 388-0480
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01 Regulation FD Disclosure.

 

The Company has issued a press release entitled “Bacterin to Present at the Rodman & Renshaw Annual Global Investment Conference” which is attached as Exhibit 99.1 and incorporated herein.

 

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01.   Financial Statements and Exhibits.

 

(d)

Exhibits.

 

Exhibit No		Description
99.1		Press Release of Bacterin International Holdings, Inc. dated August 27, 2013 entitled “Bacterin to Present at the Rodman & Renshaw Annual Global Investment Conference”

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 27, 2013	BACTERIN INTERNATIONAL HOLDINGS, INC.
	By: /s/ John Gandolfo
	Name: John Gandolfo
	Title: CFO

 

 

EXHIBIT INDEX

 

99.1

Press Release of Bacterin International Holdings, Inc. dated August 27, 2013 entitled “Bacterin to Present at the Rodman & Renshaw Annual Global Investment Conference”

 

 

 

Exhibit 99.1

 

 

 

Bacterin to Present at The Rodman & Renshaw Annual Global Investment Conference

 

 

BELGRADE, MT, August 27, 2013 -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that its CEO, Dan Goldberger and CFO, John Gandolfo, will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 9–10, 2013 at the Millennium Broadway Hotel in New York City. Bacterin's presentation will take place Tuesday, September 10, 2013 at 12:05 PM ET.

 

A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Info" section of the Company's website at www.bacterin.com. A replay of the conference presentation will also be available.

 

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

 

Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

 

Contact:

COCKRELL GROUP

877.889.1972

investorrelations@thecockrellgroup.com

cockrellgroup.com